Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel with Gemcitabine in Advanced Solid Malignancies
NCT01001221Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2009
- Primary completion
- Oct 2011
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection in solid tumor (advanced stage), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities and Objective Response Rate up to 12 months. Started Nov 2009; status: terminated.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT01001221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001221.